Pharmaceutical company Elan is to pay just over $200m to settle claims which followed an investigation of the way it marketed a medicine called Zonegran.
The agreement in principle has been reached with the US Attorney's Office for the District of Massachusetts, after an investigation by the US Department of Justice.
Zonegran was an anti-epileptic medicine which Elan sold off in 2004. The company had already set aside $206m to deal with the expected costs of the probe.
As part of the settlement, Elan expects to plead guilty to a violation of the US Federal Food, Drug and Cosmetic Act.
